NASDAQLPCN
Year
View
Form | Description | Date | Format |
---|---|---|---|
DEFA14A | Additional proxy soliciting materials - definitive | Jun 3, 2024 | ![]() ![]() ![]() ![]() |
DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") | Apr 23, 2024 | ![]() ![]() ![]() ![]() |
We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.
Form | Description | Date | Format |
---|---|---|---|
DEFA14A | Additional proxy soliciting materials - definitive | Jun 3, 2024 | ![]() ![]() ![]() ![]() |
DEF 14A | Official notification to shareholders of matters to be brought to a vote ("Proxy") | Apr 23, 2024 | ![]() ![]() ![]() ![]() |